{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:14:44Z","timestamp":1761894884765},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.reuma.2009.02.001","type":"journal-article","created":{"date-parts":[[2009,4,17]],"date-time":"2009-04-17T08:53:28Z","timestamp":1239958408000},"page":"121-127","source":"Crossref","is-referenced-by-count":2,"title":["La inhibici\u00f3n de la interleucina-6, una nueva opci\u00f3n terap\u00e9utica en la artritis reumatoide"],"prefix":"10.1016","volume":"5","author":[{"given":"Ricardo","family":"Blanco Alonso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Agudo Bilbao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2009.02.001_bib1","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/art.10623","article-title":"Therapeutic benefit after blocking interleukin-6 activity in rheumatoid arthritis with an anti-interleukin-6 receptor monoclonal antibody","volume":"46","author":"Choy","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2009.02.001_bib2","first-page":"1426","article-title":"Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase i\/ii clinical study","volume":"30","author":"Nishimoto","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2009.02.001_bib3","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","article-title":"Treatment of rheumatoid arthritis with humanized antiinterleukin 6 receptor antibody","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2009.02.001_bib4","doi-asserted-by":"crossref","unstructured":"Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy-Mod Rheumatol doi:10.1007\/s10165-008-0125-1.","DOI":"10.1007\/s10165-008-0125-1"},{"key":"10.1016\/j.reuma.2009.02.001_bib5","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI). Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"suppl 2","key":"10.1016\/j.reuma.2009.02.001_bib6","first-page":"335","article-title":"Three-year extension of the SAMURAI study confirms tocilizumab to prevent joint destruction in patients with rheumatoid arthritis","volume":"67","author":"Nishimoto","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2009.02.001_bib7","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. [Erratum in Arthritis Rheum. 2008; 58:887]","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2009.02.001_bib8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.reuma.2009.02.001_bib9","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2009.02.001_bib10","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"suppl 2","key":"10.1016\/j.reuma.2009.02.001_bib11","first-page":"89","article-title":"Tocilizumab monotherapy is superior to methotrexate monotherapy in reducing disease activity in patients with rheumatoid arthritis: The AMBITION study","volume":"67","author":"Jones","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"9 Suppl","key":"10.1016\/j.reuma.2009.02.001_bib12","first-page":"L11","article-title":"Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: The LITHE study","volume":"58","author":"Kremer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2009.02.001_bib13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.reuma.2009.02.001_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar1917","article-title":"Interleukin-6 and chronic inflammation","volume":"8","author":"Gabay","year":"2006","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.reuma.2009.02.001_bib15","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","article-title":"Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis","volume":"163","author":"Charles","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.reuma.2009.02.001_bib16","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood-2002-10-3235","article-title":"Hepcidin, a putative mediator of anemia of inflammation, is a type ii acute-phase protein","volume":"101","author":"Nemeth","year":"2003","journal-title":"Blood"},{"issue":"9 Suppl","key":"10.1016\/j.reuma.2009.02.001_bib17","first-page":"989","article-title":"Tocilizumab treatment results in rapid improvements in the signs and symptoms of moderate-to-severe rheumatoid arthritis in four patient populations with different prior therapy exposure","volume":"58","author":"Smolen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2009.02.001_bib18","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumour necrosis factor therapy","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2009.02.001_bib19","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reuma.2009.02.001_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2009.02.001_bib21","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.reuma.2009.02.001_bib22","first-page":"51","article-title":"Rheumatology in Japan, Germany, and Egypt: A comparison of medical practices","volume":"54","author":"Ito","year":"2006","journal-title":"Acta Medica et Biologica"},{"issue":"9 Suppl","key":"10.1016\/j.reuma.2009.02.001_bib23","first-page":"992","article-title":"The anti-IL6 receptor inhibitor tocilizumab (TCZ) combined with methotrexate (MTX) induces a rapid and sustained decrease of bone and cartilage degradation in patients with rheumatoid arthritis (RA)","volume":"58","author":"Garnero","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"9 Suppl","key":"10.1016\/j.reuma.2009.02.001_bib24","first-page":"1669","article-title":"Safety of tocilizumab in patients with rheumatoid arthritis: Pooled analysis of five phase 3 clinical trials","volume":"58","author":"Smolen","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"9 Suppl","key":"10.1016\/j.reuma.2009.02.001_bib25","first-page":"1670","article-title":"Safety of tocilizumab in patients with rheumatoid arthritis: An interim analysis of long-term extension trials with a mean treatment duration of 1.5 years","volume":"58","author":"Van Vollenhoven","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2009.02.001_bib26","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9 Suppl","key":"10.1016\/j.reuma.2009.02.001_bib27","first-page":"1668","article-title":"Relationship between patient characteristics and the development of serious infections in patients receiving tocilizumab: Results from long-term extension studies with a follow-up duration of 1.5 years","volume":"58","author":"Kremer","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"9 Suppl","key":"10.1016\/j.reuma.2009.02.001_bib28","first-page":"1495","article-title":"Safety and response to influenza vaccine in patients with juvenile rheumatoid arthritis recieving tocilizumab","volume":"58","author":"Shinoki","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"9 Suppl","key":"10.1016\/j.reuma.2009.02.001_bib29","first-page":"993","article-title":"Low immunogenic potential of tocilizumab in patients with rheumatoid arthritis: Analysis of four phase 3 clinical trials","volume":"58","author":"Ramos-Remus","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2009.02.001_bib30","doi-asserted-by":"crossref","first-page":"H2954","DOI":"10.1152\/ajpheart.2000.279.6.H2954","article-title":"Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow","volume":"279","author":"Suwa","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"9 Suppl","key":"10.1016\/j.reuma.2009.02.001_bib31","first-page":"1667","article-title":"Hepatic aminotransferases and bilirubin levels during tocilizumab treatment of patients with rheumatoid arthritis: Pooled analysis of five phase 3 clinical trials","volume":"58","author":"Kremer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2009.02.001_bib32","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nrm1489","article-title":"Liver regeneration: From myth to mechanism","volume":"5","author":"Taub","year":"2004","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"9 Suppl","key":"10.1016\/j.reuma.2009.02.001_bib33","first-page":"987","article-title":"Lipid and inflammatory biomarker profiles in patients receiving tocilizumab for rheumatoid arthritis: Analysis of five phase 3 clinical trials","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"9 Suppl","key":"10.1016\/j.reuma.2009.02.001_bib34","first-page":"1672","article-title":"Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis with elevated low density lipoprotein cholesterol: Analysis of five phase 3 clinical trials mark C","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2009.02.001_bib35","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1196\/annals.1351.039","article-title":"Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis","volume":"1069","author":"Seriolo","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.reuma.2009.02.001_bib36","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1136\/ard.2006.066191","article-title":"Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis","volume":"66","author":"Popa","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2009.02.001_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/03009740500474578","article-title":"Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy","volume":"35","author":"Dahlqvist","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.reuma.2009.02.001_bib38","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/art.22809","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X09000527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X09000527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T21:21:26Z","timestamp":1684963286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X09000527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S1699258X09000527"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2009.02.001","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}